Patent EA-017171-B1 (EA)
Title: COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH αδ LIGANDS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
Inventor: LEONARDI AMEDEO
IPC: A61K45/06
Filed: 2007-12-21
Abstract: The present invention relates to the use of a αδ calcium channel subunit ligand and of a non-steroidal anti-inflammatory drug in a combination treatment of a lower urinary tract disorder and the non-steroidal anti-inflammatory drug. The subject of the present invention is the use of the αδ calcium channel subunit (Ad) ligand selected from gabapentin or pregabalin, (1R,5R,6S)-6-aminomethyl-6-carboxymethylbicyclo[3.2.0]heptane, 3-(1-aminomethylcyclohexylmethyl)-4H-1,2,4- oxadiazol-5-one, 5-(1-aminomethylcyclohexylmethyl)-1H-tetrazole, (3S,4S)-(1-aminomethyl-1-carboxymethyl-3,4-dimethylcyclopentane, (1α,3α,5α)-(3-aminomethyl-3-carboxymethylbicyclo[3.2.0]heptane, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylheptanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline or (2S,4S)-4-(3-fluorobenzyl)proline, or a mixture of two or more thereof in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of a non-steroidal anti-inflammatory drug (NSAID). Another subject of the invention is the use of the non-steroidal anti-inflammatory drug in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of the αδ calcium channel subunit (Ad) ligand selected from gabapentin or pregabalin, (1R,5R,6S)-6-aminomethyl-6-carboxymethylbicyclo[3.2.0]heptane, 3-(1-aminomethylcyclohexylmethyl)-4H-1,2,4-oxadiazol-5-one, 5-(1-aminomethylcyclohexylmethyl)-1H-tetrazole, (3S,4S)-(1-aminomethyl-1-carboxymethyl-3,4-dimethylcyclopentane, (1α,3α,5α)-(3-aminomethyl-3-carboxymethylbicyclo[3.2.0]heptane, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylheptanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline or (2S,4S)-4-(3-fluorobenzyl)proline, or a mixture of two or more thereof. Preferably the non-steroidal anti-inflammatory drug is a COX-inhibitor. It is also preferable that the non-steroidal anti-inflammatory drug is celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide or sulindac. One more subject of the invention is the use of compbination of at least one αδ calcium channel subunit (Ad) ligand and at least one non-steroidal anti-inflammatory drug for the concurrent or post-administration in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder. Another subject of the invention is the use of the αδ calcium channel subunit (Ad) ligand for the preparation of a medicament for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of a non-steroidal anti-inflammatory drug (NSAID). One more subject of the invention is the use of the non-steroidal anti-inflammatory drug for the preparation of a medicament for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of the αδ calcium channel subunit (Ad) ligand.